The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts
Open accessAbstract
Tertiary lymphoid structures (TLS) are lymphoid aggregates resembling secondary lymphoid organs found at sites of inflammation. TLS have been identified in tumors (TA-TLS), where they are associated with enhanced patient survival, but the mechanisms underlying their formation are unknown. We show here that TA-TLS development in murine melanomas is orchestrated by fibroblasts with characteristics of lymphoid tissue organizer cells that are induced by tumor necrosis factor receptor signaling. Fibroblast organization into reticular networks is initiated by CD8 T-cells, but full TA-TLS development depends on CXCL13-mediated recruitment of B-cells that express lymphotoxin-α1/β2. Some of these elements were also overrepresented in TA-TLS of human tumors. Immune checkpoint blockade induced more and larger TA-TLS that were more often organized with discrete T- and B-cell zones. This work provides a platform for manipulating TA-TLS as a cancer immunotherapy strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731 · cited 1×
“Recent publications reported that TA-TLS presence prior to treatment was associated with a favorable response to immunotherapy in patients with cancer (Griss et al., 2019; Cabrita et al., 2020; Petitprez et al., 2020; Helmink et al., 2020).”
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Cabrita, R., Lauss, M., Sanna, A., Donia, M., Skaarup Larsen, M., Mitra, S., Johansson, I., Phung, B., Harbst, K., Vallon-Christersson, J., et al. (2020) · Nature · doi:10.1038/s41586-019-1914-8 · Cited by 2,374
Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087
B cells are associated with survival and immunotherapy response in sarcoma
Petitprez, F., de Reyniès, A., Keung, E. Z., Chen, T. W.-W., Sun, C.-M., Calderaro, J., Jeng, Y.-M., Hsiao, L.-P., Lacroix, L., Bougoüin, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1906-8 · Cited by 1,942
Tertiary lymphoid structures in the era of cancer immunotherapy
Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Thommen, D. S., Koelzer, V. H., Herzig, P., Roller, A., Trefny, M., Dimeloe, S., Kiialainen, A., Hanhart, J., Schill, C., Hess, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0057-z · Cited by 1,161 · cited 1×
“CXCL13-expressing T FH cells and CD8 T cells have been identified in human breast tumors and non-small cell lung cancer, respectively (Gu-Trantien et al., 2017; Thommen et al., 2018), and it is likely that such cells are also found in melanoma TA-TLS.”
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134
Förster, R., Mattis, A. E., Kremmer, E., Wolf, E., Brem, G., & Lipp, M. (1996) · Cell · doi:10.1016/s0092-8674(00)81798-5 · Cited by 1,129
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
Liu, T., Han, C., Wang, S., Fang, P., Ma, Z., Xu, L., & Yin, R. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0770-1 · Cited by 860 · cited 2×
“These results were consistent with the possibility that S.C. and I.P. tumors are dominated by mutually exclusive populations of CAF with FAP + pro-tumor (Liu et al., 2019) and FAP neg LTo phenotypes.”
Cited by
Tertiary lymphoid structures in cancer
Schumacher, T. N., & Thommen, D. S. (2022) · Science · doi:10.1126/science.abf9419 · Cited by 1,142
Fridman, W. H., Meylan, M., Petitprez, F., Sun, C.-M., Italiano, A., & Sautès-Fridman, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00619-z · Cited by 657
Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities
Laumont, C. M., Banville, A. C., Gilardi, M., Hollern, D. P., & Nelson, B. H. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00466-1 · Cited by 524
Pathological angiogenesis: mechanisms and therapeutic strategies
Dudley, A. C., & Griffioen, A. W. (2023) · Angiogenesis · doi:10.1007/s10456-023-09876-7 · Cited by 495
Tertiary lymphoid structures and B cells: An intratumoral immunity cycle
Fridman, W. H., Meylan, M., Pupier, G., Calvez, A., Hernandez, I., & Sautès-Fridman, C. (2023) · Immunity · doi:10.1016/j.immuni.2023.08.009 · Cited by 326
Metadata
- Authors
- Rodriguez, A. B., Peske, J. D., Woods, A. N., Leick, K. M., Mauldin, I. S., Meneveau, M. O., Young, S. J., Lindsay, R. S., Melssen, M. M., Cyranowski, S., Parriott, G., Conaway, M. R., Fu, Y.-X., Slingluff, C. L., & Engelhard, V. H.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 36
- Issue
- 3
- Pages
- 109422
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W3186518830
- Cited by
- 271
- References
- 95
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. https://app.cochat.ai/papers/10.1016/j.celrep.2021.109422
- The paper
- Rodriguez, A. B., Peske, J. D., Woods, A. N., Leick, K. M., Mauldin, I. S., Meneveau, M. O., Young, S. J., Lindsay, R. S., Melssen, M. M., Cyranowski, S., Parriott, G., Conaway, M. R., Fu, Y.-X., Slingluff, C. L., & Engelhard, V. H. (2021). Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Reports. https://doi.org/10.1016/j.celrep.2021.109422
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.